Monitor BP in Patients on Injectable CGRP Antagonists (Aimovig, Etc)
You'll hear concerns about using an injectable CGRP antagonist (Aimovig, etc) for migraine prevention in patients with CV risks.
Most data suggest that CGRP antagonists have minimal CV impact. But it's mostly short-term and in young patients without CV risks.
Now an FDA review suggests new-onset or worsening hypertension with Aimovig (erenumab)...prompting labeling updates.